相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Original Research Tumour mutational burden predicts resistance to EGFR/ BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer
Giovanni Randon et al.
EUROPEAN JOURNAL OF CANCER (2022)
Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF(V600E) metastatic colorectal cancer
Van K. Morris et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer
Andreas Seeber et al.
CLINICAL CANCER RESEARCH (2022)
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer
Elena Elez et al.
NATURE MEDICINE (2022)
Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib plus /- binimetinib or alpelisib
Sanne C. F. A. Huijberts et al.
BRITISH JOURNAL OF CANCER (2021)
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
Hiroyuki Arai et al.
CLINICAL CANCER RESEARCH (2021)
Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR plus /- MEK inhibitors
E. Elez et al.
ANNALS OF ONCOLOGY (2021)
Three-year Survival Rate after Radiofrequency Ablation for Surgically Resectable Colorectal Lung Metastases: A Prospective Multicenter Study
Takaaki Hasegawa et al.
RADIOLOGY (2020)
APC Mutation Marks an Aggressive Subtype of BRAF Mutant Colorectal Cancers
Lochlan J. Fennell et al.
CANCERS (2020)
Cross-talk between SOX2 and TGF beta Signaling Regulates EGFR-TKI Tolerance and Lung Cancer Dissemination
Ming-Han Kuo et al.
CANCER RESEARCH (2020)
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper
Arvind Dasari et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC
Sehhoon Park et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma
Debora Basile et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Adaptive mutability of colorectal cancers in response to targeted therapies
Mariangela Russo et al.
SCIENCE (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Guangming Chen et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
Yang Liu et al.
CANCER CELL (2018)
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Min Yuen Teo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
CANCER DISCOVERY (2018)
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Theo A. Knijnenburg et al.
CELL REPORTS (2018)
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types
Marie-Claire Wagle et al.
NPJ PRECISION ONCOLOGY (2018)
RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation
Helen H. N. Yan et al.
GUT (2017)
Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
Jeremy C. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer
Robin M. J. M. van Geel et al.
CANCER DISCOVERY (2017)
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence
Katherine R. Singleton et al.
CELL REPORTS (2017)
SIFT missense predictions for genomes
Robert Vaser et al.
NATURE PROTOCOLS (2016)
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
Daniele Oddo et al.
CANCER RESEARCH (2016)
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
Rona Yaeger et al.
CLINICAL CANCER RESEARCH (2015)
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
Filippo Pietrantonio et al.
EUROPEAN JOURNAL OF CANCER (2015)
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Dishevelled Promotes Wnt Receptor Degradation through Recruitment of ZNRF3/RNF43 E3 Ubiquitin Ligases
Xiaomo Jiang et al.
MOLECULAR CELL (2015)
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
Leanne G. Ahronian et al.
CANCER DISCOVERY (2015)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun et al.
NATURE (2014)
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy
Libero Santarpia et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors
Bon-Kyoung Koo et al.
NATURE (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
BRAF Mutation in Metastatic Colorectal Cancer.
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Wilms tumor suppressor WTX negatively regulates WNT/β-catenin signaling
Michael B. Major et al.
SCIENCE (2007)
Mechanisms of TGF-β signaling from cell membrane to the nucleus
YG Shi et al.
CELL (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
